Stock Commentary - Europe - week to Sept 22, 2008

28 September 2008

EUROPEAN: bourses ended an extremely volatile week to September 22 mixed, despite rises of up to nearly 10% on some markets ahead of the week-end, when the US government announced plans to help the toxic mortgage situation and the UK moved to restrict short-selling in financials. Drug majors largely underperformed their local markets. Roche was a casualty on the ZURICH exchange, due to a likely delay in the approval if it rheumatoid arthritis drug candidate Actemra (tocilizumab), seen as an important addition to the firm's product portfolio (see page 23). In PARIS, Sanofi-Aventis gave up more than its previous week's gain on news of a new chief executive (Marketletters September 15 and 22), falling 8.1% while the CAC 40 rose 1.3%. On the BRUSSELS bourse, Solvay and UCB strongly outperformed the BEL-20's 0.2% dip, both seeing a 6.1% advance.

LONDON: share prices in the drug sector saw wild variations. Little Alizyme continued to rocket, moving up a further 37.5%, on top of the already 83% gains made over the two previous weeks, on hopes that the entry of its obesity drug candidate cetilistat into Phase III clinical trials would trigger a milestone from Japanese partner Takeda, but more importantly rumors that it could be acquired by the latter. Biotechnology firm Protherics advanced 8.5%, after UK drug developer BTG announced plans to acquire the firm at 60 pence a share, a premium of 45.5% to its closing price on September 17 (Marketletter September 22). Antisoma was out of favor, falling 7.0% as investors await news of whether partner Swiss drug major Novartis will move forward with the develop ment of the UK-firm's ASA404.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight